<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is a disease characterised by peripheral <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, as well as by pancreatic <z:hpo ids='HP_0006279'>beta cell dysfunction</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This process is in part due to elevated blood <z:chebi fb="105" ids="17234">glucose</z:chebi> and free fatty acids--termed glucolipotoxicity </plain></SENT>
<SENT sid="2" pm="."><plain>The traditional pathway of treating type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in a stepwise manner, beginning with life style modifications and continuing with oral hypoglycaemic agents leads to a protracted period of unnecessary <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>A new approach, targeted at alleviating the deleterious effects of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and elevated free fatty acids by acutely lowering both with intensive insulin therapy, has yielded prolonged remissions in therapy in which only diet was necessary to maintain normoglycaemia </plain></SENT>
<SENT sid="4" pm="."><plain>This new approach, its rationale, benefits and misgivings are discussed in this review </plain></SENT>
</text></document>